A pharmaceutical company in TBNA joins hands with US counterpart to jointly develop gene therapy products

2019-10-22 15:57

The reporter learned from the Science and Technology Bureau of Tianjin Binhai New Area (TBNA for short) that recently, Tianjin Cansino Biotech Co., Ltd., a biopharmaceutical company in TBNA, has entered into a strategic cooperation with Ocugen, Inc. of the United States, and will jointly develop and produce OCU400, a gene therapy product for hereditary retinal diseases.

It is claimed that Ocugen is a US-based biopharmaceutical company focused on the clinical stage, and is committed to developing innovative therapies for rare and unmedicated eye diseases. With this collaboration, Cansino will provide a full suite of chemical/production/control (CMC) developments for Ocugen's first gene-modified therapy technology platform, the OCU400, through advanced R&D and transformation technologies, production facilities and a world-class innovation management team. Clinical materials accelerate the adoption of clinical trials and eventually commercialization.

津滨网版权所有,未经书面授权禁止使用 违法和不良信息举报电话: 022-25204288 服务邮箱:jinbinwang2015@163.com
互联网新闻信息服务许可证:12120170004 备案序号:津ICP备11000547号津公网安备 12010702000020号